U.S. Office REITs Stock News

StoneX Group (SNEX) is back in the spotlight after recent media coverage of its share price rise, strong revenue and earnings figures, solid balance sheet, and ongoing debate around whether the current valuation is stretched. See our latest analysis for StoneX Group. The share price momentum in StoneX Group has been strong, with a 30 day share price return of 19.73%, a 90 day move of 91.93%, and a 1 year total shareholder return of 132.28%, pointing to steadily building enthusiasm around the...

Mettler-Toledo International recently reported year-over-year growth in both revenue and net profit, alongside earnings per share that significantly exceeded market expectations, even as its overall financial position was characterized as weak and detailed cash flow and liability data were not disclosed. An interesting angle for investors is the very large institutional shareholding proportion of the company, which increased further last quarter and now ranks it first within its Office...

Coach, part of Tapestry (NYSE:TPR), has launched &Coach, a digital luxury content platform co-created with Gen Z. The platform focuses on social first storytelling and participatory campaigns, with younger creators embedded in the process. &Coach is intended to reshape how the Coach brand builds community and relevance with younger luxury consumers. Tapestry, trading at $145.87, sits behind Coach as its flagship brand and is leaning into a content driven approach to connect with younger...

In recent days, Freeport-McMoRan has benefited from rallies in copper, gold, and silver prices amid improving global economic sentiment and easing inflation pressures from lower crude oil prices. This upswing in metals prices aligns with analysts’ optimism about long-term copper demand, reinforcing the importance of copper, gold, and molybdenum to Freeport-McMoRan’s cash generation and margins. Next, we’ll examine how this metals-driven optimism, particularly around copper demand, could...

Euronet Worldwide (EEFT) stock has been drawing attention after a period of mixed share performance, with the price closing at $67.03 and returns weaker over the past year and past 3 months. See our latest analysis for Euronet Worldwide. Recent trading suggests Euronet Worldwide’s short term share price momentum has been patchy, and the share price weakness lines up with a much steeper decline in total shareholder return over the past five years. If Euronet Worldwide’s recent swings have you...

Credit Acceptance recently amended its revolving secured credit facility with Fifth Third Bank and other lenders, extending the facility’s revolving period to June 22, 2029 and lowering the interest rate from SOFR plus 197.5 basis points to SOFR plus 175.0 basis points on the US$270.5 million currently outstanding. The company also announced a CFO transition, with long-serving finance chief Jay D. Martin retiring and experienced corporate finance leader Joseph Billante stepping in,...

Carter’s Inc. recently launched “Dadfirmations,” a national Father’s Day hotline and in-store recording experience that lets children share uplifting messages for dads and father figures, alongside an expanded partnership with 23XI Racing and Boys & Girls Clubs of America to offer a new online parenting resource with expert-backed guidance and real parent stories. These initiatives highlight Carter’s effort to deepen emotional ties with families and position the brand as a broader parenting...

Earlier this month, Harrow re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a steroid-sparing prescription therapy for vernal keratoconjunctivitis in children and adults, supported by a broad push on physician education, patient access, and affordability. This move targets a historically underserved pediatric eye disease where many patients are inadequately controlled on antihistamines and face risks from long-term steroid use, potentially reshaping VKC treatment patterns. We’ll...

Tariffs, shifting trade rules, and pressure on global supply chains are reshaping how investors think about US manufacturing stocks. Instead of relying on smooth cross-border trade, markets are reassessing companies that produce more at home and can better control their costs and inputs. This article looks at three US Domestic Manufacturing screener stocks that are directly exposed to these trade headlines and may react in different ways as policies evolve. Each stock is assessed on its...

With Kevin Warsh preparing for his first post-meeting press conference and the Federal Reserve keeping rates at 3.6% while inflation sits at 4.2%, many investors are rethinking how much risk they want to carry. Large-cap defensive stocks, often backed by steady dividends and stronger balance sheets, can look relatively appealing when rate cuts seem less likely and market swings pick up. This article highlights 3 stocks from our Large-Cap Defensive Stocks screener that appear positively...

In mid-June 2026, QIAGEN expanded its QIAcuity digital PCR ecosystem with new gene expression assays, a high-multiplex RNA kit, enhanced residual DNA testing, upgraded analysis software and greater automation for life sciences and biopharma labs. This build-out, including software that standardizes analysis and Hamilton-enabled robotic workflows, points to a stronger push into higher-throughput, regulated applications. Next, we’ll consider how this expansion of QIAcuity’s automated,...

With markets under pressure from a more hawkish Federal Reserve tone, rising 10-year Treasury yields, and broad weakness across sectors, it can feel harder than ever to decide which large-cap stocks deserve space in your portfolio. Quality, financial strength, and consistent execution take on extra importance when borrowing costs rise and megacap tech stocks such as Meta, Microsoft, and Amazon come under renewed scrutiny. This article highlights three large-cap stocks from a Quality Large-Cap...

In recent days, Credicorp reported strong year-over-year growth in revenue and net profit, alongside a higher dividend yield than both the Banks - Foreign industry and the S&P 500, with its annualized dividend rising sharply compared with last year. What stands out is how this combination of robust financial results and a materially increased dividend has reinforced expectations for higher earnings per share in fiscal 2026. With this stronger dividend profile as a backdrop, we’ll now examine...

Tutor Perini (TPC) stock is in focus after the company secured a $651.8 million task order from Naval Facilities Engineering Systems Command Pacific to upgrade electrical infrastructure at Naval Base Guam. See our latest analysis for Tutor Perini. The Guam contract arrives at a time when Tutor Perini shares have been gaining attention, with a 7-day share price return of 13.34% and a year-to-date share price return of 12.31%. The 1-year total shareholder return sits at 86.00%, and the 3-year...

Shell’s decision to hire PJT Partners (PJT) to advise on a potential sale of offshore wind farm assets, in a deal reportedly exceeding US$1b, has put fresh attention on PJT Partners stock. See our latest analysis for PJT Partners. At a share price of US$155.01, PJT Partners has seen short term share price weakness, with the stock down over the past week and month. However, the 90 day share price return of 18.65% and 3 year total shareholder return of 121.07% point to momentum that has built...

With the Federal Reserve hinting at possible rate hikes in 2026 and inflation holding at 4.2%, value stocks are back in focus for investors who care about price tags as much as potential. Higher-for-longer rates can reward companies with resilient balance sheets and sensible valuations, while putting pressure on those priced for perfection. This article highlights three value stocks from our screener that are closely exposed to the latest Fed and inflation news. It explains why some investors...

GeneDx Holdings (WGS) stock is in focus after the company appointed Mark Gardner as President, effective June 15, 2026. This leadership change could influence how investors view its execution and growth priorities. See our latest analysis for GeneDx Holdings. The appointment of Mark Gardner comes after a volatile stretch for GeneDx Holdings, with the share price falling 57.35% year to date but rising 32.16% over the past month, while three year total shareholder return remains very large. If...

AAON (AAON) raised its 2026 revenue growth outlook to 40% to 45%, citing record backlog, expanding capacity, and improving production execution, particularly at BASX, as key supports for the stock's recent move. See our latest analysis for AAON. The latest guidance upgrade lands on top of strong momentum in AAON stock, with a 90 day share price return of 66.6% and a 1 year total shareholder return of 86.58%. However, the 30 day share price move has been roughly flat, which may hint that...

Ambarella (AMBA) stock fell 18.05% after GoPro secured a patent victory against Insta360. This development raised legal and commercial questions for Ambarella’s camera ecosystem partners, even as its latest quarterly earnings results outperformed expectations. See our latest analysis for Ambarella. Over the past year, Ambarella’s total shareholder return of 24.61% contrasts with a share price that is down 12.35% year to date and 16.48% over 30 days. This suggests momentum has cooled recently...

In recent months, UroGen Pharma resolved a patent dispute with Teva Pharmaceuticals by granting a non-exclusive license for a generic version of Jelmyto starting 15 September 2030, while reporting modest Jelmyto growth and significantly stronger first-quarter sales for its newer therapy, Zusduri. This combination of a long-dated generic entry and early commercial momentum for Zusduri reshapes how investors weigh UroGen’s product concentration and revenue-risk profile. With the Teva...

Insider Selling and Valuation Concerns Put Impinj Stock in Focus Impinj (PI) shares fell 5.0% on June 16, 2026, after renewed attention on valuation, with the stock trading 5.5% above its estimated intrinsic value and recent insider selling totaling US$49.4 million. See our latest analysis for Impinj. The latest drop in Impinj's share price fits into a mixed picture, with a 23.29% 90 day share price return contrasting with a year to date share price decline of 31.35%. At the same time, the 5...

The Centers for Medicare & Medicaid Services previously issued an updated National Coverage Determination that broadened access to transcatheter aortic valve replacement (TAVR), aligning with Edwards Lifesciences’ Sapien 3 devices that already carry expanded FDA labels for asymptomatic patients. This clearer and more inclusive reimbursement framework could be pivotal for Edwards Lifesciences’ transcatheter heart valve portfolio by supporting wider real-world adoption and potentially shifting...

If you are wondering whether Corcept Therapeutics stock is still attractively priced after a strong run, the key question now is how its current share price compares with a reasonable view of fair value. The stock last closed at US$81.75, with returns of 4.6% over the past week, 48.3% over the past month, 114.0% year to date, 14.8% over the past year, 264.0% over three years, and 267.3% over five years. These figures naturally raise questions about how much of the story might already be...

The Fed’s hawkish turn, with rates held at 3.5 to 3.75% and the next move likely a hike, has quickly reshaped expectations for dividend stocks. Higher yields on cash and bonds can pressure income stocks, but solid dividend growth companies with healthy balance sheets can still play a role for investors looking for reliable cash flows and potential income growth. This article looks at three dividend growth stocks from our screener that appear well positioned against this new rate backdrop and...